Impact of apolipoprotein(a) isoform size on lipoprotein(a) lowering in the HPS2-THRIVE study
<h4>Background</h4> <p>Genetic studies have shown lipoprotein(a) (Lp[a]) to be an important causal risk factor for coronary disease. Apolipoprotein(a) isoform size is the chief determinant of Lp(a) levels, but its impact on the benefits of therapies that lower Lp(a) remains unclea...
Main Authors: | Parish, S, Hopewell, J, Hill, M, Marcovina, S, Valdes-Marquez, E, Haynes, R, Offer, A, Pedersen, T, Baigent, C, Collins, R, Landray, M, Armitage, J |
---|---|
Format: | Journal article |
Language: | English |
Published: |
American Heart Association
2018
|
Similar Items
-
Environmental and genetic risk factors for myopathy in Chinese participants from HPS2-THRIVE
by: Hopewell, J, et al.
Published: (2012) -
Serious adverse effects of extended-release niacin/laropiprant: results from the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) Trial
by: Haynes, R, et al.
Published: (2019) -
Effects of extended release niacin/laropiprant in 25,673 high-risk individuals receiving statin-based therapy: the HPS2-THRIVE randomized placebo-controlled trial
by: Landray, M, et al.
Published: (2014) -
Impact of lipoprotein(a) levels and apolipoprotein(a) isoform size on risk of coronary heart disease.
by: Hopewell, J, et al.
Published: (2014) -
Impact of lipoprotein(a) levels and apolipoprotein(a) isoform size on risk of coronary heart disease
by: Hopewell, J, et al.
Published: (2014)